References
- Reck M, Rodríguez-Abreu D, Robinson AG, et al. Keynote-024 investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833.
- Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–2028.
- Morgensztern D, Herbst RS. Nivolumab and pembrolizumab for non-small cell lung cancer.clin. Cancer Res. 2016 Aug 1;22(15):3713–3717.
- Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627–1639.
- Kerr KM, Tsao MS, Nicholson AG, et al. IASLC Pathology Committee. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thoraconcol. 2015 Jul;10(7):985–989.
- Khanal N, Ganti AK. Emerging targeted therapies in non-small cell lung cancer. Expert Rev Anticancer Ther. 2016;16(2):177–187.
- Waqar SN, Morgensztern D. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era? Expert Rev Clinimmunol. 2015;11(8):871–873.
- Addeo R, Caraglia M, Iuliano G. Pembrolizumab:the value of PDL1 biomarker in head and neck cancer. Expert Opinbiolther. 2016;16(9):1075–1078.
- Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508.
- Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22(18):4585–4593.